The authors found the titers are stable for about 3 months and overall, have high neutralizing activity, especially among the moderate and high titer categories. They concluded this evidence further validates the applicability of using antibody titers to refer COVID-19 recovered individuals for plasma donation. The authors attributed the titer increase among low and moderate categories over time to a slower seroconversion in mild cases.